Novartis begins Zolgensma study after FDA’s hold lifts

Novartis begins Zolgensma study after FDA’s hold lifts

Aiming to expand the use of Zolgensma, Novartis has announced the launch of a new phase three study following the FDA’s decision to remove restrictions and partial clinical trial hold. Novartis plans to evaluate the use of Zolgensma to treat patients (aged 2-18) for...